Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ginkgo Bioworks has entered a multi-year collaboration with Boehringer Ingelheim worth up to $405 million to discover natural-product-based therapeutics. The…
Ginkgo Bioworks (NYSE: DNA) partners with Boehringer Ingelheim to leverage Ginkgo's natural product discovery platform; Ginkgo receives upfront research fees…
Ginkgo Bioworks and Boehringer Ingelheim have agreed a collaboration worth up to $405 million to search for new natural-product-based therapeutics, one of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Ginkgo Bioworks and Boehringer Ingelheim entered a drug discovery partnership leveraging Ginkgo's metagenomic library to identify lead therapeutic molecules. Ginkgo received upfront research fees plus potential R&D, regulatory and commercial milestones totaling $405M, plus unspecified royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim International GmbH / Ginkgo Bioworks Holdings, Inc. (this deal) | 2023 | $405M | — |
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) | 2015 | $12.4B | 81 |
| Boehringer Ingelheim International GmbH / Abexxa Biologics Inc. | 2021 | — | — |
| Boehringer Ingelheim International GmbH / T3 Pharmaceuticals AG | 2023 | $508M | — |
| Boehringer Ingelheim International GmbH / Cue Biopharma, Inc. | 2025 | $357M | — |
| Boehringer Ingelheim International GmbH / Synaffix B.V. | 2025 | $1.3B | — |
| Boehringer Ingelheim International GmbH / Immunitas Therapeutics, Inc. | 2026 | — | — |
← Browse all deals · How we score deals
More: 2023 deals · Boehringer Ingelheim International GmbH deals · Multiple (undisclosed) deals